Eltrombopag

[MAF] Eltrombopag Tablet 25 mg, 50 mg

1. Treatment of immune thrombocytopenia lasting six months or longer from diagnosis in patients who are intolerant or refractory to other treatments (e.g. corticosteroids, immunosuppressants).

2. Treatment of severe aplastic anaemia in patients who are refractory to immunosuppressive therapy (comprising horse anti-thymocyte globulin plus ciclosporin for at least 3 months) and have marrow cellularity <25% (or 25 to 50% with <30% residual haematopoietic cells), with at least 2 of the following:
   • neutrophils <0.5 x 10⁹/l
   • platelets <20 x 10⁹/l
   • reticulocyte count <20 x 10⁹/l (<60 x 10⁹/l for automated reticulocyte counting)

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

04/01/2022 Eltrombopag for treating immune thrombocytopenia and severe aplastic anaemia

The Ministry of Health’s Drug Advisory Committee has recommended:

Eltrombopag 25 mg and 50 mg tablets for treating:

• immune thrombocytopenia lasting six months or longer from diagnosis in patients who are intolerant or refractory to other treatments (e.g. corticosteroids, immunosuppressants); and

• severe aplastic anaemia in patients who are refractory to immunosuppressive therapy (comprising horse anti-thymocyte globulin plus ciclosporin for at least three months) and have marrow cellularity <25% (or 25 to 50% with <30% residual haematopoietic cells), with at least two of the following:

  • neutrophils <0.5 x 10⁹/l

  • platelets <20 x 10⁹/l

  • reticulocyte count <20 x 10⁹/l (<60 x 10⁹/l for automated reticulocyte counting).

Eltrombopag should be prescribed by a haematologist with experience in managing immune thrombocytopenia and severe aplastic anaemia.

Subsidy status

[R] Eltrombopag 25 mg and 50 mg tablets are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indications.

[NR] MAF assistance does not apply to the use of eltrombopag for treating newly diagnosed severe aplastic anaemia.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration